We will keep you informed with the latest news
MT awarded NCI SBIR Phase II grant
Molecular Theranostics has been awarded a two-year, $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Award to study the magnetic imaging efficacy of MT218 in prostate cancer patients and safety, after successfully completing a clinical trial in 30 healthy volunteers.
Funded by the NIH, the award supports a diverse portfolio of startups and small businesses across technology areas and markets to stimulate technological innovation, meet Federal research and development (R&D) needs, and increase commercialization to transition R&D into impact.
MT Attend BIO Investor Forum 2019
Molecular Theranostics CEO Yajuan Li, Ph.D. presenting at Bio Investor Forum in San Francisco, California
Topic is "Targeted peptide based agents for tumor precise imaging"
MT CEO Interview with Proactive
"Molecular Theranostics LLC CEO Yajuan Li spoke with Proactive at the 2019 BIO Investor Forum in San Francisco. "